Department of Gynecology and Mastology, Hospital Getúlio Vargas, Federal University of Piauí, Teresina, Piauí, Brazil.
Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):165-7. doi: 10.1016/j.ejogrb.2011.06.020. Epub 2011 Jul 7.
This study aims to evaluate the effect of raloxifene on the expression of human telomerase reverse transcriptase (hTERT) in invasive ductal breast carcinoma of postmenopausal women.
This study included 20 postmenopausal women with invasive, stage II, estrogen receptor-positive ductal carcinoma diagnosed by incisional biopsy, who received 60 mg of raloxifene orally for 28 days prior to definitive surgery. On the 29th day of treatment, definitive surgery was performed and a second tumor sample was taken for analysis. The catalytic subunit of telomerase (hTERT) was evaluated semiquantitatively by immunohistochemistry in the tumor samples obtained prior to and following raloxifene use and the results were analyzed using the McNemar test (p<0.05).
The samples of 17 patients (85%) were classified as positive for telomerase expression prior to raloxifene treatment, while only 6 (30%) remained positive following raloxifene treatment (p<0.0026).
In the present study, raloxifene significantly reduced the expression of hTERT in estrogen receptor-positive breast tumors from postmenopausal women.
本研究旨在评估雷洛昔芬对绝经后妇女浸润性导管乳腺癌中人类端粒酶逆转录酶（hTERT）表达的影响。
本研究纳入了 20 名经切开活检诊断为浸润性、Ⅱ期、雌激素受体阳性的导管癌的绝经后妇女，这些患者在接受确定性手术前接受了 60mg 雷洛昔芬口服治疗 28 天。在治疗的第 29 天进行了确定性手术，并采集了第二个肿瘤样本进行分析。采用免疫组织化学法对半定量评估肿瘤样本中端粒酶的催化亚单位（hTERT），并使用 McNemar 检验（p<0.05）对结果进行分析。
在接受雷洛昔芬治疗前，17 名患者（85%）的样本被分类为端粒酶表达阳性，而在接受雷洛昔芬治疗后，只有 6 名患者（30%）仍为阳性（p<0.0026）。
在本研究中，雷洛昔芬显著降低了绝经后妇女雌激素受体阳性乳腺癌中 hTERT 的表达。
Zotero 插件